Act Raloxifene 60 mg (Raloxifene Hydrochloride TABLET) 60 MG

ACT Raloxifene 60 mg tablets are a selective estrogen receptor modulator (SERM) used for managing osteoporosis and reducing breast cancer risk. This oral medication is designed to support bone health and hormonal balance.

Strength

60 MG

Manufacturer / TM Owner

TEVA CANADA LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Raloxifene is commonly used to treat and prevent osteoporosis in postmenopausal women, helping to maintain bone density and reduce fracture risk. It is also prescribed to lower the risk of invasive breast cancer in high-risk women. Raloxifene works by mimicking estrogen's positive effects on bones without stimulating the uterus or breasts.

Side Effects

Common effects of Raloxifene may include hot flashes, leg cramps, and fluid retention. Some users report mild nausea or digestive discomfort. These effects vary and are not experienced by everyone. Consult a healthcare provider for personalized advice.

Precautions & Warnings

Raloxifene should be used with caution in individuals with a history of blood clots or liver disease. Regular monitoring may be recommended. Always follow the guidance of a healthcare professional when starting or adjusting medication.

Avoid Interactions

Raloxifene may interact with certain medications, including blood thinners and estrogen-containing products. Alcohol consumption should be moderated. Inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Raloxifene is used to treat and prevent osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in high-risk individuals.

Raloxifene is typically taken orally, usually once a day. Follow the instructions provided by your healthcare provider for the best results.

Common side effects may include hot flashes, leg cramps, and fluid retention. Some users may experience mild nausea or digestive discomfort.

Raloxifene may interact with certain medications, including blood thinners and estrogen-containing products. Always consult a healthcare provider before combining medications.

Raloxifene should be used with caution in individuals with a history of blood clots or liver disease. Regular monitoring may be recommended.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.